MRX-12

MRX-12 is an investigational antibacterial drug candidate from MicuRx being developed as a **new-class agent targeting multidrug-resistant Gram-negative bacteria**. Publicly available company materials identify it only at a high level as part of MicuRx's anti-superbug pipeline, without disclosing a specific chemical name, molecular target, or detailed mechanism of action. Available pipeline summaries indicate the program was aimed at Gram-negative bacterial infections, but third-party pipeline tracking sources list the asset as discontinued, and no clear evidence of clinical-stage development, regulatory approval, marketed status, formulation details, or branded product naming was identified.